IGM Biosciences stock target cut at RBC but reaffirmed at Outperform

On Tuesday, RBC Capital revised its price target for IGM Biosciences (NASDAQ: NASDAQ:IGMS), a biotechnology firm, lowering it to $17 from the previous $20. Despite the reduction, the firm has maintained an Outperform rating on the stock.

The adjustment follows the company's decision to discontinue the development of aplitabart, a move that transitions IGM Biosciences into a focused autoimmune disease company, primarily concentrating on T-cell engager therapies.

The analyst from RBC Capital noted that the discontinuation was unfortunate but believed that the new direction towards autoimmune specialization could enhance the company's narrative and attract investor interest. The focus on this area is expected to align with the sectors of highest promise and also serve as a strategy to conserve the company's financial resources.

Following a recent discussion with the management of IGM Biosciences, RBC Capital adjusted its financial model to reflect the latest corporate developments. This reassessment resulted in the new price target of $17.

"With stock dipping below this post-market, we would be buyers into key upcoming autoimmune data from imvotamab," said the analysts.

In other recent news, IGM Biosciences reported a Q2 net loss of $0.79 per share, deviating from the initially projected gain of $0.21 per share. H.C. Wainwright revised its full-year 2024 net loss projection for IGM Biosciences to $2.31 per share, an improvement from the previously estimated net loss of $3.27 per share.

Various analyst firms have updated their ratings for IGM Biosciences. Jefferies and Morgan Stanley maintained their Buy and Equalweight ratings respectively, while JPMorgan downgraded the company from 'Neutral' to 'Underweight'.

These developments underscore the company's commitment to its new strategic direction and its efforts to advance its clinical programs. The company's financial position appears robust, with a cash runway extended into 2027, expected to cover current plans and development milestones for both imvotamab and IGM-2644.

InvestingPro Insights

Recent data from InvestingPro sheds additional light on IGM Biosciences' financial position and market performance. The company's market capitalization stands at $981.13 million, reflecting its current valuation in the biotech sector. Despite the recent setback with aplitabart, IGM Biosciences has shown strong market performance, with a 62.32% price return over the past month and an impressive 143.59% return over the last three months.

InvestingPro Tips highlight that IGM Biosciences holds more cash than debt on its balance sheet, which could provide financial flexibility as it pivots to focus on autoimmune diseases. This aligns with the company's strategy to conserve resources, as mentioned in the article. Additionally, the tip that liquid assets exceed short-term obligations suggests a solid near-term financial position.

However, it's important to note that IGM Biosciences is quickly burning through cash and is not profitable over the last twelve months. This underscores the importance of the company's strategic shift and the potential impact of upcoming data on imvotamab.

For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide further insights into IGM Biosciences' financial health and market prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.